Guardant Health acquired early cancer‑detection startup MetaSight Diagnostics for $59 million upfront plus up to $90 million in contingent payments, expanding its screening portfolio alongside its Shield colorectal cancer test. Guardant provided 2026 guidance projecting substantial growth in Shield volumes and revenue, driven by partnerships (including Quest Diagnostics) and potential guideline inclusion. Management described the traction as early but accelerating, and the MetaSight buy adds technology and IP that can be integrated into Guardant’s broader screening roadmap. The deal reflects consolidation among companies building blood‑based cancer screening franchises.